Evaluated N=175

Randomized n=84

Allocated to Exemestane (n=22)
- Discontinued (n=2)
- Withdrew Consent 2
- Adverse Events 0
- Excluded From Analysis Because of a Lack of Suppression of Estrogen Levels (n=1)
- Evaluable (n=19)

Allocated to Letrozole (n=20)
- Discontinued (n=0)
- Withdrew Consent 0
- Adverse Events 0
- Excluded From Analysis Because of a Lack of Suppression of Estrogen Levels (n=1)
- Evaluable (n=19)

Allocated to Anastrozole (n=21)
- Discontinued (n=2)
- Withdrew Consent 1
- Adverse Events 1
- Excluded From Analysis Because of a Lack of Suppression of Estrogen Levels (n=3)
- Evaluable (n=16)

Allocated to Placebo (n=21)
- Discontinued (n=1)
- Withdrew Consent 0
- Adverse Events 1
- Excluded From Analysis Because of a Lack of Suppression of Estrogen Levels (n=0)
- Evaluable (n=20)